Economic evaluation of PCV21 in vaccine-naïve adults aged 19–64 years with underlying medical conditions in the United States
The findings suggest that the use of PCV21 (Capvaxive) in adults aged 19-64 years with underlying medical conditions in the US can prevent a significant number of pneumococcal disease cases and deaths while demonstrating favorable economic outcomes across various scenarios.
Authors
- Elamin H. Elbasha (ORCID: https://orcid.org/0000-0002-9993-8036)
- Kwame Owusu‐Edusei (ORCID: https://orcid.org/0000-0002-4519-2857)
- Zinan Yi (ORCID: https://orcid.org/0009-0002-4997-3121)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Merck Biopharma Co., Ltd. (Japan) (JP)
- Decision Sciences (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1080/13696998.2025.2496070
- Citations
- 2
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 2.71